Status:
COMPLETED
An Observational Study on Long-Term Efficacy and Safety of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis (FAct)
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
This observational study will evaluate the long-term efficacy and safety of RoActemra/Actemra (tocilizumab in participants of the ACT SURE clinical trial and further patients with moderate to severe r...
Eligibility Criteria
Inclusion
- Adult patients, \>18 years of age
- Participants in the ACT-SURE trial, or patients with moderate to severe rheumatoid arthritis starting or receiving RoActemra/Actemra
Exclusion
- Contra-indications for RoActemra/Actemra
Key Trial Info
Start Date :
December 31 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 19 2017
Estimated Enrollment :
215 Patients enrolled
Trial Details
Trial ID
NCT01483326
Start Date
December 31 2010
End Date
June 19 2017
Last Update
May 1 2019
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Jan Van Breemen Instituut
Amsterdam, Netherlands, 1056 AB
2
Gelre Ziekenhuis; Reumatology
Apeldoorn, Netherlands, 7300 DS
3
Rijnstate Ziekenhuis; Afdeling Reumatologie
Arnhem, Netherlands, 6815 AD
4
Amphia ziekenhuis, locatie langendijk
Breda, Netherlands, 4819 EV